Author: IN8bio, Inc

Posted Date:

April 3, 2026

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio, Inc

April 3, 2026
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results – Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

IN8bio, Inc

March 12, 2026
IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio, Inc

February 24, 2026
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

IN8bio, Inc

February 9, 2026
IN8bio to Present at Upcoming Investor and Scientific Conferences in February

IN8bio, Inc

February 3, 2026